Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash & Equivalents (2020 - 2025)

Journey Medical (DERM) has disclosed Cash & Equivalents for 6 consecutive years, with $24.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 11.07% year-over-year to $24.9 million, compared with a TTM value of $24.9 million through Sep 2025, up 11.07%, and an annual FY2024 reading of $20.3 million, down 25.89% over the prior year.
  • Cash & Equivalents was $24.9 million for Q3 2025 at Journey Medical, up from $20.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $49.1 million in Q4 2021 and bottomed at $8.2 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $26.6 million, with a median of $24.1 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents soared 498.55% in 2021, then crashed 78.4% in 2023.
  • Year by year, Cash & Equivalents stood at $49.1 million in 2021, then tumbled by 34.8% to $32.0 million in 2022, then dropped by 14.37% to $27.4 million in 2023, then dropped by 25.89% to $20.3 million in 2024, then grew by 22.87% to $24.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for DERM at $24.9 million in Q3 2025, $20.3 million in Q2 2025, and $21.1 million in Q1 2025.